Canine atopic dermatitis, commonly known as dog allergies, is a chronic skin condition that affects many dogs. It is caused by an allergic reaction of some kind, either to external allergens like pollens, dust mites or molds, or to internal allergens like certain foods. Symptoms include itching, redness, skin lesions, hair loss, and skin infections. Treatment options include medicated shampoos, topical creams and ointments, oral medications, immunotherapy, and dietary modifications.
The global canine atopic dermatitis treatment drugs market is estimated to be valued at US$ 360 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
One of the key drivers for the canine atopic dermatitis treatment drugs market is rising pet obesity. Obese and overweight dogs are more likely to develop allergies and chronic conditions like canine atopic dermatitis. According to the Association for Pet Obesity Prevention, 60% of U.S. dogs are either overweight or obese. Efforts by veterinarians and pet owners to address this issue of pet obesity are expected to increase demand for atopic dermatitis treatment drugs over the forecast period. In addition, rising pet ownership in developing regions like Asia Pacific is also anticipated to boost the market growth.
SWOT Analysis
Strength: Canine atopic dermatitis has a high prevalence in dogs worldwide. Skin conditions affect quality of life for both dogs and their owners. Treatment drugs provide relief from itching and skin lesions, improving health outcomes.
Brands like Apoquel and Cytopoint are well-established leaders in alleviating symptoms. They are well-researched and trusted by veterinarians. However, generic brands may bring lower costs.
Weakness: Treatment depends on continuous usage to maintain relief. If owners forget doses or discontinue medication, symptoms return. Some medications have side effects like lethargy, diarrhoea, or vomiting that reduce compliance.
Opportunity: Education campaigns can boost awareness of relieving skin allergies as a lifelong condition rather than temporary. This stabilizes long-term demand. Pet insurance coverage expansion may reimburse drug costs, increasing accessibility.
Threats: Alternative therapies gain interest due to perceptions of fewer side effects or 'natural' status. Their evidence is often limited compared to pharmaceuticals’ research backing. Macro factors like recession may impact discretionary spending on veterinary care.
Key Takeaways
The Global Canine Atopic Dermatitis Treatment Drugs Market Size is expected to witness high growth. The global canine atopic dermatitis treatment drugs market is estimated to be valued at US$ 360 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031.
Regional analysis: North America accounts for over 35% market share currently due to high density of veterinary clinics and hospitals. Europe follows as the second largest regional market supported by growing pet ownership in countries like the UK, Spain, Italy, and Germany. Asia Pacific shows fastest growth due to rising pet humanization and increasing sales of pet insurance policies in nations like Japan, Australia, South Korea and China.
Key players: Key players operating in the canine atopic dermatitis treatment drugs market are Zoetis, Virbac, AB Science, Elanco Animal Health, and Dechra Pharmaceuticals.
For More details on the topic:
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek